Floatz Rating
C39/100
Confidence
Indicative
Sponsor
BioEclipse Therapeutics
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04282044CT.gov Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ovarian Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| CRX100 (this asset) | BioEclipse Therapeutics | P1 | C · 39 |
| Trabectedin | AGO Research GmbH | P4 | BBB |
| Mirvetuximab Soravtansine | AstraZeneca | P3 | BBB |
| Carboplatin | University of Washington | P3 | BB |
| Irinotecan | OHSU Knight Cancer Institute | P2 | BB |
| Olaparib | Imunon | P4 | BB |
| Palbociclib | University Medical Center Groningen | P4 | BB |
| Lenvatinib | University Medical Center Groningen | P4 | BB |
| Durvalumab | AGO Research GmbH | P2 | BB |
+42 more in the Ovarian Carcinoma cohort
Other indications for CRX100
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Osteosarcoma | — | P1 | CC · 41 |
| Melanoma | — | P1 | CC · 41 |
| Hepatocellular Carcinoma | — | P1 | C · 37 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. CRX100 in Ovarian Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/crx100-ovarian-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →